Hosted on MSN27d
Kidney disease drug developer Maze files for $100M IPOMaze Therapeutics (MAZE), which is developing treatments for chronic kidney disease, has filed to raise $100M through an initial public offering. While the company didn't disclose terms in its SEC ...
A Quick Take On Maze Therapeutics, Inc. Maze Therapeutics, Inc. (NASDAQ:MAZE) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback